{"id":"kn057","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OX40 is a co-stimulatory molecule expressed on activated T cells that plays a critical role in T cell proliferation and survival. By agonizing OX40, KN057 enhances T cell activation and expansion, promoting anti-tumor immunity. This mechanism is designed to work synergistically with other immunotherapies to improve anti-tumor efficacy.","oneSentence":"KN057 is a monoclonal antibody that targets and blocks the OX40 receptor to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:53.850Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in combination with other immunotherapies)"}]},"trialDetails":[{"nctId":"NCT06312475","phase":"PHASE3","title":"Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2024-01-09","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":53},{"nctId":"NCT06569108","phase":"PHASE3","title":"Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2024-04-01","conditions":"Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor","enrollment":125},{"nctId":"NCT05421429","phase":"PHASE2","title":"KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia","status":"COMPLETED","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2022-07-07","conditions":"Hemophilia","enrollment":24},{"nctId":"NCT06747416","phase":"PHASE2","title":"KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2025-09-02","conditions":"Hemophilia a and B","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KN057","genericName":"KN057","companyName":"Suzhou Alphamab Co., Ltd.","companyId":"suzhou-alphamab-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KN057 is a monoclonal antibody that targets and blocks the OX40 receptor to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (in combination with other immunotherapies).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}